Synlogic announces data presentations at the 2023 synthetic biology: engineering, evolution & design (seed) conference

Cambridge, mass., may 24, 2023 (globe newswire) -- synlogic, inc. (nasdaq: sybx), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at the 2023 synthetic biology: engineering, evolution & design (seed) conference being held may 30 – june 2, 2023 in los angeles, ca. the company's oral presentation focuses on synlogic's development of a synthetic biotic drug candidate for the potential treatment of homocystinuria (hcu), a rare metabolic disease caused by an inborn error of metabolism. the company's poster presentations highlight preclinical and clinical data. presentation details are provided below.
SYBX Ratings Summary
SYBX Quant Ranking